查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950496

長效生長抑制素類似物市場：按產品類型、適應症、給藥途徑、通路、病患年齡層分類的全球預測（2026-2032年）

Long-acting Somatostatin Analogues Market by Product Type, Indication, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，長效生長抑制素類似物市場規模將達到 36.5 億美元，到 2026 年將達到 40.6 億美元，到 2032 年將達到 78.5 億美元，複合年成長率為 11.55%。

關鍵市場統計數據
基準年 2025 36.5億美元
預計年份：2026年 40.6億美元
預測年份 2032 78.5億美元
複合年成長率 (%) 11.55%

策略性應用：將長效生長抑制素類似物定位為不斷發展的慢性內分泌和神經內分泌疾病治療路徑的核心要素

長效生長抑制素類似物的治療領域已從一種小眾治療選擇轉變為慢性內分泌和神經內分泌疾病管理的核心組成部分。過去十年，臨床醫生和醫療保健系統越來越依賴緩釋製劑來提高患者依從性、減少給藥頻率，並穩定需要持續荷爾蒙抑制的疾病的生化指標。隨著臨床實務的發展，人們對患者便利性、療效評估和整合式診療路徑的期望也隨之提高。

不斷發展的臨床實踐、製劑創新和綜合患者服務如何重塑生長抑制素療法的開發和商業化

長效生長抑制素類似物的市場環境正經歷著一場變革，其驅動力來自臨床實踐的改變、產品創新以及醫療保健期望的轉變。臨床醫生日益關注治療的連續性和患者報告的療效，這使得給藥間隔、注射耐受性和可預測的動態變得尤為重要。同時，生產商也積極推行生命週期策略，致力於改善製劑、開發新型給藥裝置並擴大適應症，以確保藥物持續的治療價值。

評估2025年美國關稅變化對供應鏈、籌資策略和治療獲取動態的系統性影響

貿易和關稅政策的變化會對治療方法的生產、定價和供應產生重大的下游影響。 2025年美國關稅政策迫使供應鏈相關人員重新評估其籌資策略，尤其是那些擁有跨境生產設施的高價值活性藥物原料藥和成品藥生產商。為因應這項變化，生產商已實現供應商多元化，加快了生產回流，並與貿易條件有利地區的委託製造合作，以減輕關稅波動的影響。

詳細的細分分析揭示了產品類型、適應症細微差別、給藥途徑、通路和年齡層如何驅動差異化的策略重點。

細緻的細分框架闡明了臨床需求和供應模式的差異如何影響產品策略和商業化重點。產品類型維度突顯了Lanreotide緩釋凝膠、Octreotide長效製劑和Pasireotide肽長效製劑的獨特治療屬性，其製劑特性和給藥途徑會影響臨床醫師的偏好和給藥流程。基於適應症的區分突顯了肢端肥大症、庫欣氏症和神經內分泌腫瘤（NETs）的不同使用模式。神經內分泌腫瘤進一步細分為胃腸胰神經內分泌腫瘤（NETs）和肺神經內分泌腫瘤（NETs），每種腫瘤都有其自身的診斷路徑和多學科治療需求。

美洲、歐洲、中東和非洲以及亞太地區的區域背景和市場准入因素將影響臨床應用和分銷策略。

區域趨勢在全球範圍內影響醫療服務取得、臨床實踐規範和醫療服務提供者策略。在美洲，我們持續看到專科中心與大型醫院系統之間密切合作，這影響著競標行為、藥品分銷物流和病患支援服務。在這些市場，支付方和醫療服務提供者之間的協作在製定藥品目錄和確保複雜慢性病患者的醫療服務取得方面發揮核心作用。

藥物研發公司、專業製造商和服務合作夥伴之間的競爭與合作趨勢將決定生長抑制素類似物市場的長期定位。

此領域的競爭格局由成熟的原廠藥廠、專業生產商和支持製劑及給藥方式創新的合約研發機構 (CDO) 共同構成。主要企業採取了多元化策略，將投資範圍擴展至生命週期管理、適應症拓展和病患服務，以增強產品差異化。與臨床網路和關鍵意見領袖 (KOL) 的合作仍然是推動指南採納和建立真實世界證據計畫（以證明藥物的長期安全性和耐受性）的關鍵所在。

為領導者提供切實可行的建議，以整合製劑創新、供應鏈韌性和支付方合作，從而改善臨床應用和長期可及性。

產業領導者應優先考慮將臨床差異化、營運韌性和支付方價值主張結合的策略。首先，投資於改進的製劑和給藥技術，以減輕給藥負擔並提高耐受性，將有助於增強臨床醫生的偏好和患者的依從性。這些改進應輔以強力的真實世界證據項目，以證明其臨床和人體療效。其次，生產和籌資策略多元化將降低貿易中斷風險，並實現更可預測的供應。同時，與區域契約製造組織 (CMO) 建立策略合作夥伴關係可以加速本地市場准入和產能擴張。

採用透明的多方法研究途徑（臨床醫師參與、監管審查、供應鏈分析）可以得出可靠、可操作的結論。

本調查方法結合了定性初步研究和定量檢驗，以確保證據基礎的全面性和可靠性。初步研究包括對內分泌科醫生、神經內分泌腫瘤科醫生、醫院藥劑師、採購人員和支付方代表的訪談，以了解臨床實踐、報銷趨勢和分銷挑戰等方面的真實觀點。此外，也邀請由臨床專家組成的顧問小組對這些調查進行補充，以檢驗真實世界的治療路徑和對未滿足需求的解釋。

對臨床機會、營運需求和策略重點的綜合分析揭示了生長抑制素治療中持續創造價值的促進因素

累積分析表明，在臨床上對持續生化指標控制的需求以及對以患者為中心的醫療服務日益成長的期望的推動下，長效生長抑制素類似物在慢性內分泌和神經內分泌疾病的治療中正發揮著越來越重要的戰略作用。製劑和給藥方式的創新，結合強化的病人支持服務，為提高病人的用藥依從性和就醫體驗提供了切實的機會。此外，受區域報銷複雜性、供應鏈脆弱性和支付方審查等因素影響的更廣泛的商業環境，要求生產商採取將臨床差異化與營運韌性相結合的綜合策略。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 長效生長抑制素類似物市場（依產品類型分類）

  • Lanreotide緩釋凝膠
  • OctreotideLAR
  • PasireotideLAR

9. 依適應症分類的長效生長抑制素類似物市場

  • 肢端肥大症
  • 庫欣氏症
  • 神經內分泌腫瘤
    • 胃腸胰神經內分泌腫瘤
    • 肺神經內分泌腫瘤

10. 依給藥途徑分類的長效生長抑制素類似物市場

  • 深層皮下注射
  • 肌肉內注射

11. 長效生長抑制素類似物市場（依分銷通路分類）

  • 醫院藥房
  • 郵購藥房
  • 零售藥房

12. 依患者年齡層別分類的長效生長抑制素類似物市場

  • 成人版
  • 兒童

13. 各地區長效生長抑制素類似物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 長效生長抑制素類似物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國長效生長抑制素類似物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國長效生長抑制素類似物市場

17. 中國長效生長抑制素類似物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amneal Pharmaceuticals, Inc.
  • Bachem Holding AG
  • BioSynthema Inc.
  • Camurus AB
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • Chiasma, Inc.
  • Cipla Limited
  • Crinetics Pharmaceuticals, Inc.
  • Dauntless Pharmaceuticals, Inc.
  • Debiopharm Group
  • EVER Pharma GmbH
  • Ferring Pharmaceuticals
  • Ipsen Pharma
  • Midatech Pharma PLC
  • Mylan NV
  • Novartis AG
  • Peptron Inc.
  • Pfizer Inc.
  • Recordati SpA
  • Sandoz International GmbH
  • ScinoPharm Taiwan Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-4F7A6D4FD89F

The Long-acting Somatostatin Analogues Market was valued at USD 3.65 billion in 2025 and is projected to grow to USD 4.06 billion in 2026, with a CAGR of 11.55%, reaching USD 7.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.65 billion
Estimated Year [2026] USD 4.06 billion
Forecast Year [2032] USD 7.85 billion
CAGR (%) 11.55%

A strategic introduction framing long-acting somatostatin analogues as central elements of evolving chronic endocrine and neuroendocrine care pathways

The therapeutic class of long-acting somatostatin analogues has shifted from niche treatment options to central components of chronic endocrine and neuroendocrine disease management. Over the last decade, clinicians and healthcare systems have increasingly relied on extended-release formulations to improve adherence, reduce administration frequency, and stabilize biochemical control in conditions that require sustained suppression of hormone activity. As clinical practice evolves, so do expectations around patient convenience, outcomes measurement, and integrated care pathways.

Consequently, stakeholders across the value chain-clinicians, payers, distributors, and manufacturers-are re-evaluating product positioning and service models. Regulatory authorities have emphasized safety monitoring and post-approval evidence generation, prompting manufacturers to expand real-world evidence programs and patient support services. In parallel, technological refinements in formulation and delivery have created opportunities to reduce variability in therapeutic effect and to differentiate products through improved tolerability and administration experience. These dynamics create a complex environment where strategic clarity and operational agility determine the pace at which new and existing therapies deliver sustained clinical and commercial value.

How clinical practice evolution, formulation innovation, and integrated patient services are reshaping the development and commercialization of somatostatin therapies

The landscape for long-acting somatostatin analogues is undergoing transformative shifts driven by clinical practice, product innovation, and changing expectations across care settings. Clinicians are increasingly emphasizing continuity of care and patient-reported outcomes, which has elevated the importance of dosing intervals, injection tolerability, and predictable pharmacodynamics. Simultaneously, manufacturers are pursuing lifecycle strategies that emphasize formulation improvements, novel delivery devices, and expanded label claims to sustain therapeutic relevance.

Another significant shift concerns the integration of digital health and patient support services. Remote monitoring, adherence reminders, and virtual nursing services are complementing pharmacologic therapy to enhance adherence and capture real-world performance data. These services influence payer negotiations and contracting approaches because they demonstrate additional value beyond active pharmaceutical ingredients. Furthermore, the competitive environment is shaped by regulatory pathways that favor robust post-marketing evidence and by an evolving payer landscape that scrutinizes long-term outcomes and cost-effectiveness. Taken together, these forces are redefining how products are developed, launched, and sustained clinically and commercially, reinforcing the need for coordinated strategies across R&D, market access, and stakeholder engagement.

Evaluating the systemic consequences of United States tariff changes in 2025 on supply chains, procurement strategies, and therapeutic access dynamics

Policy shifts in trade and tariffs can have significant downstream implications for how therapies are manufactured, priced, and delivered. In the context of United States tariffs introduced in 2025, supply chain stakeholders faced pressure to reassess sourcing strategies, particularly for high-value active pharmaceutical ingredients and finished-dose manufacturers with cross-border production footprints. Manufacturers responded by diversifying supplier bases, accelerating onshoring initiatives, and engaging contract manufacturers in regions with favorable trade terms to reduce exposure to tariff volatility.

These adaptations influenced procurement strategies among health systems and wholesalers, who sought greater transparency on landed costs and longer-term contracting to stabilize supply. In parallel, payers and integrated delivery networks intensified their scrutiny of total cost of therapy, emphasizing not only acquisition cost but also administration logistics and the impact of adherence on downstream health resource utilization. Importantly, regulatory and procurement teams collaborated to protect continuity of care by prioritizing quality-certified suppliers and contingency stock strategies. While individual organizational responses varied, a common thread was an emphasis on resiliency-ensuring uninterrupted patient access through diversified sourcing, strengthened supplier relationships, and enhanced logistics planning.

In-depth segmentation insights revealing how product type, indication nuance, administration route, distribution pathways, and age cohorts drive differentiated strategic priorities

A nuanced segmentation framework clarifies how differentiated clinical needs and delivery models shape product strategy and commercialization priorities. The product-type dimension highlights distinct therapeutic attributes across Lanreotide Autogel, Octreotide LAR, and Pasireotide LAR, where formulation properties and dosing profiles influence clinician preference and administration workflows. Indication-based differentiation underscores divergent utilization patterns across Acromegaly, Cushing's Disease, and Neuroendocrine Tumors, with Neuroendocrine Tumors further delineated into Gastroenteropancreatic NETs and Pulmonary NETs, each presenting unique diagnostic pathways and multidisciplinary care requirements.

Route-of-administration segmentation contrasts Deep Subcutaneous Injection with Intramuscular Injection, with implications for training requirements, administration setting selection, and patient experience. Distribution channel stratification-spanning Hospital Pharmacies, Mail Order Pharmacies, and Retail Pharmacies-reveals differing inventory models, reimbursement interfaces, and opportunities for value-added services such as home nursing for injections or integrated patient support programs. Finally, patient age group segmentation between Adult and Pediatric populations directs attention to dosing adjustments, safety profiles, and educational needs. Together, these dimensions inform targeted commercial strategies and support the design of tailored clinical programs that address the specific needs of prescribers, patients, and payers in each segment.

Regional landscapes and access considerations across the Americas, Europe Middle East and Africa, and Asia-Pacific that determine clinical uptake and distribution strategies

Regional dynamics influence access, clinical practice norms, and supplier strategies across the global landscape. The Americas continue to exhibit strong integration between specialist centers and large hospital systems, which shapes tendering behavior, distribution logistics, and the structure of patient support services. In these markets, coordinated efforts between payers and providers are central to formulary decisions and to ensuring access for complex chronic conditions.

In the Europe, Middle East & Africa region, heterogeneity in regulatory frameworks and reimbursement mechanisms requires tailored market entry strategies. Multinational manufacturers often need adaptive pricing models and targeted evidence generation plans to meet diverse HTA and reimbursement expectations. Meanwhile, the Asia-Pacific region presents rapidly evolving healthcare infrastructure, with a growing emphasis on improving diagnosis rates and expanding specialty care capacity. Manufacturers seeking traction in Asia-Pacific must balance investments in clinician education, local regulatory engagement, and distribution partnerships to navigate fragmented payer landscapes and to scale access effectively. Across all regions, supply chain resilience, regulatory alignment, and localized patient engagement are critical to sustained uptake.

Competitive and collaboration trends among originators, specialized manufacturers, and service partners that determine long-term positioning in the somatostatin analogue arena

Competitive dynamics in the class are shaped by a mix of established originator companies, specialty manufacturers, and contract development organizations that support formulation and delivery innovation. Leading manufacturers have pursued multifaceted strategies combining life-cycle management, label expansion, and investments in patient services to reinforce product differentiation. Collaboration with clinical networks and key opinion leaders has remained central to driving guideline inclusion and informing real-world evidence programs that substantiate long-term safety and tolerability profiles.

At the same time, third-party manufacturers and specialized injectables partners play an increasingly important role by offering advanced formulation expertise and scalable production capacity. Strategic alliances between originator companies and local distributors or manufacturers help navigate regulatory hurdles and optimize market access in geographies with complex reimbursement environments. Across the competitive landscape, successful players balance R&D investment in improved delivery systems with commercial investments in payer engagement and patient support, recognizing that clinical performance and service offerings together determine long-term clinical adoption and formulary positioning.

Actionable recommendations for leaders to align formulation innovation, supply resilience, and payer engagement to enhance clinical adoption and long-term access

Industry leaders should prioritize strategies that align clinical differentiation with operational resilience and payer-facing value propositions. First, investing in formulation and delivery improvements that reduce administration burden and enhance tolerability will strengthen clinician preference and patient adherence; these improvements should be paired with robust real-world evidence programs to document clinical and humanistic outcomes. Second, diversifying manufacturing and sourcing strategies reduces exposure to trade disruptions and enables more predictable supply, while strategic partnerships with regional CMOs can accelerate local market entry and capacity scaling.

Third, embedding comprehensive patient support services, including injection training, adherence monitoring, and digital reminders, can materially influence persistence and overall treatment value. Fourth, proactive payer engagement that emphasizes total cost of care, outcome-based contracting options, and shared risk arrangements will be increasingly important to secure formulary placement. Finally, targeted investments in pediatric labeling and specialty clinic education expand the addressable clinical base and demonstrate a commitment to clinician and patient needs. By integrating these priorities, leaders can build resilient, differentiated portfolios that respond to clinical expectations and payer demands alike.

Transparent and multi-method research approach combining clinician engagement, regulatory review, and supply chain analysis to ensure robust actionable conclusions

The research methodology combined primary qualitative engagement with quantitative validation to ensure a comprehensive and credible evidence base. Primary inputs included interviews with endocrinologists, neuroendocrine tumor specialists, hospital pharmacists, procurement leaders, and payer representatives to capture frontline perspectives on clinical practice, reimbursement dynamics, and distribution challenges. These engagements were complemented by advisory panels with clinical experts to vet interpretations of real-world care pathways and unmet needs.

Secondary research leveraged peer-reviewed literature, regulatory agency documentation, clinical trial registries, and public filings to map therapeutic mechanisms, safety profiles, and label distinctions among long-acting somatostatin analogues. Supply chain and trade policy analyses drew on customs and trade policy publications and logistics reports to contextualize tariff impacts and sourcing responses. Data synthesis emphasized triangulation across sources, with cross-validation steps to reconcile divergent viewpoints. Throughout the process, analytical rigor was maintained by documenting assumptions, applying sensitivity checks where appropriate, and subjecting key findings to expert review to ensure reproducibility and practical relevance.

Concluding synthesis of clinical opportunities, operational imperatives, and strategic priorities that determine sustained value delivery for somatostatin therapies

The cumulative analysis underscores that long-acting somatostatin analogues occupy an increasingly strategic role in chronic endocrine and neuroendocrine care, driven by clinical demand for sustained biochemical control and by evolving expectations around patient-centered delivery. Innovation in formulations and delivery mechanisms, coupled with enhanced patient support services, creates tangible opportunities to improve adherence and patient experience. Moreover, the broader commercial environment-shaped by regional reimbursement complexity, supply chain vulnerabilities, and payer scrutiny-requires manufacturers to adopt integrated approaches that bridge clinical differentiation and operational resilience.

Looking ahead, stakeholders who align product development with real-world evidence generation, invest in resilient sourcing strategies, and engage payers with data on total clinical value will be best positioned to support clinicians and patients. The interplay between clinical innovation and pragmatic considerations such as distribution channel design and age-specific labeling will determine the pace and breadth of adoption. Ultimately, a coordinated strategy that prioritizes patient outcomes, regulatory compliance, and supply continuity will drive sustainable value for all stakeholders involved in delivering long-acting somatostatin therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Long-acting Somatostatin Analogues Market, by Product Type

  • 8.1. Lanreotide Autogel
  • 8.2. Octreotide LAR
  • 8.3. Pasireotide LAR

9. Long-acting Somatostatin Analogues Market, by Indication

  • 9.1. Acromegaly
  • 9.2. Cushing's Disease
  • 9.3. Neuroendocrine Tumors
    • 9.3.1. Gastroenteropancreatic NETs
    • 9.3.2. Pulmonary NETs

10. Long-acting Somatostatin Analogues Market, by Route Of Administration

  • 10.1. Deep Subcutaneous Injection
  • 10.2. Intramuscular Injection

11. Long-acting Somatostatin Analogues Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Mail Order Pharmacies
  • 11.3. Retail Pharmacies

12. Long-acting Somatostatin Analogues Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Pediatric

13. Long-acting Somatostatin Analogues Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Long-acting Somatostatin Analogues Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Long-acting Somatostatin Analogues Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Long-acting Somatostatin Analogues Market

17. China Long-acting Somatostatin Analogues Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amneal Pharmaceuticals, Inc.
  • 18.6. Bachem Holding AG
  • 18.7. BioSynthema Inc.
  • 18.8. Camurus AB
  • 18.9. Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • 18.10. Chiasma, Inc.
  • 18.11. Cipla Limited
  • 18.12. Crinetics Pharmaceuticals, Inc.
  • 18.13. Dauntless Pharmaceuticals, Inc.
  • 18.14. Debiopharm Group
  • 18.15. EVER Pharma GmbH
  • 18.16. Ferring Pharmaceuticals
  • 18.17. Ipsen Pharma
  • 18.18. Midatech Pharma PLC
  • 18.19. Mylan N.V.
  • 18.20. Novartis AG
  • 18.21. Peptron Inc.
  • 18.22. Pfizer Inc.
  • 18.23. Recordati S.p.A.
  • 18.24. Sandoz International GmbH
  • 18.25. ScinoPharm Taiwan Ltd.
  • 18.26. Sun Pharmaceutical Industries Ltd.
  • 18.27. Teva Pharmaceutical Industries Ltd.
  • 18.28. Wockhardt Ltd.
  • 18.29. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY LANREOTIDE AUTOGEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY LANREOTIDE AUTOGEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY LANREOTIDE AUTOGEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY OCTREOTIDE LAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY OCTREOTIDE LAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY OCTREOTIDE LAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PASIREOTIDE LAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PASIREOTIDE LAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PASIREOTIDE LAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ACROMEGALY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ACROMEGALY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ACROMEGALY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY CUSHING'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY CUSHING'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY CUSHING'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY GASTROENTEROPANCREATIC NETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY GASTROENTEROPANCREATIC NETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY GASTROENTEROPANCREATIC NETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PULMONARY NETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PULMONARY NETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PULMONARY NETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DEEP SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DEEP SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DEEP SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY MAIL ORDER PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY MAIL ORDER PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY MAIL ORDER PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GCC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. GCC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 122. GCC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. GCC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GCC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. G7 LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. G7 LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 143. G7 LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. G7 LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. G7 LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. NATO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. NATO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 150. NATO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. NATO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NATO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)